On August 19, INSILICO fell 5.01% in regular trading, trading at HKD 39.38/share, with turnover of HKD 419 million, extending the prior session's decline.

On the news front, the company announced after market close on August 18 that it plans to invest approximately RMB 302.5 million through wholly-owned subsidiaries to co-establish a biopharmaceutical private equity fund with Pudong Construction and Value Partners Group. The fund, tentatively named Insilico Pufa Value Partners (Shanghai) Private Equity Fund, targets a total scale of RMB 1.01 billion and will focus on investments in biopharmaceuticals and related sectors. The joint venture formed as part of the structure is expected to become an indirect non-wholly-owned subsidiary consolidated into the group's financial statements. The substantial capital commitment has raised market concerns over near-term cash flow diversion from core R&D operations.

Within the Life Sciences Tools and Services sector, the overall tone remained weak. Among individual stocks, Genscript Biotech rose 1.56%, WuXi Biologics fell 1.44%, WuXi AppTec fell 1.27%, WuXi XDC fell 2.36%, and Pharmaron fell 1.55%, reflecting broad sector pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)